Article
What Works When Treating Granulomatous Disease in Genetically Undefined CVID? A Systematic Review.
Frontiers in immunology - 1 Jan 2020
van Stigt Astrid C, Dik Willem A, Kamphuis Lieke S J, Smits Bas M, van Montfrans Joris M, van Hagen P Martin, Dalm Virgil A S H, IJspeert Hanna
Abstract excerpt
Background: Granulomatous disease is reported in at least 8-20% of patients with common variable immunodeficiency (CVID). Granulomatous disease mainly affects the lungs, and is associated with significantly higher morbidity and mortality. In half of patients with granulomatous disease, extrapulmonary manifestations are found, affecting e.g. skin, liver, and lymph nodes. In literature various therapies have been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.